Loading clinical trials...
Loading clinical trials...
Phase II Trial of Rituximab Plus 2CdA in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Conditions
Interventions
Rituximab
2-CdA
Locations
5
Austria
Universitätsklinikum Graz
Graz, Austria
Universitaetsklinik Innsbruck/ Klinik für Innere Medizin
Innsbruck, Austria
Krankenhaus der Stadt Linz
Linz, Austria
Universitaetsklinik f. Innere Medizin III
Salzburg, Austria
AKH Wien / Universitaetsklinik fuer Innere Medizin I
Vienna, Austria
Start Date
May 1, 2008
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
December 24, 2013
NCT06859008
NCT01815749
NCT01769222
NCT01261247
NCT04465162
NCT00536601
Lead Sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions